Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care
The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide.
This afternoon felt like either a fund blew up or the margin clerks were taking a bunch of dumb over-leveraged money out to the woodshed to put them out of their misery.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Baxter International (BAX) cut its dividend because of the upcoming sale of the Kidney Care business, high debt and leverage, lower earnings per share, and free cash flow.
The U.S. faces a critical shortage of IV fluids due to Hurricane Helene's damage to Baxter's North Carolina plant, forcing hospitals to delay surgeries. Federal efforts to rebuild and import supplies aim to ease the crisis by year-end.
Baxter International resumes IV fluid shipments from international sites after Hurricane Helene disrupted production at its North Carolina plant, which supplies 60% of U.S. IV fluids. FDA approves temporary imports to ease the shortage.
U.S. Senator Amy Klobuchar has called on HHS Secretary Xavier Becerra to address the national IV solution shortage following the closure of Baxter's facility due to Hurricane Helene, which compromises patient care and poses risks of price gouging.
Medtronic Inc. is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets. Here are some highlights from a quantitative analysis of the stock.
Baxter has agreed to sell its Kidney Care segment to Carlyle for $3.8 billion. Baxter will receive about $3.5 billion in cash, with net after-tax proceeds estimated at $3 billion. Post-sale, Baxter aims for 4-5% annual sales growth and a 16.5% adjusted operating margin by 2025.
Baxter surpasses Q2 expectations with adjusted EPS of $0.68 and sales of $3.812 billion. Sales rose 3% reported and 4% constant currency, driven by Pharmaceuticals, Medical Products, and Healthcare Systems. 2024 sales growth outlook increased to 3%.
